Trials / Not Yet Recruiting
Not Yet RecruitingNCT07433192
POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.
Multicenter Observational Study POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes in Real-world Clinical Practice.
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Servier Russia · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
In this non-interventional study, the effectiveness and tolerability of Lusefi® in adult patients with type 2 diabetes will be evaluated.
Detailed description
This single-arm study is planned to include patients who, in routine clinical practice, have been prescribed 2.5 mg of Lusefi® once daily as type 2 diabetes treatment. If the response to the treatment is insufficient, the attending physician in routine clinical practice may increase the daily dose to 5 mg once daily. The total duration of observation within this study will be approximately 6 months. Describing hypoglycemic effectiveness of luseogliflozin, its effect on the metabolic and hemodynamic parameters in patients with type 2 diabetes in real-world clinical practice.
Conditions
Timeline
- Start date
- 2026-03-30
- Primary completion
- 2027-03-01
- Completion
- 2027-09-01
- First posted
- 2026-02-25
- Last updated
- 2026-02-25
Source: ClinicalTrials.gov record NCT07433192. Inclusion in this directory is not an endorsement.